| Year |
Citation |
Score |
| 2024 |
Guarducci C, Nardone A, Russo D, Nagy Z, Heraud C, Grinshpun A, Zhang Q, Freelander A, Leventhal MJ, Feit A, Cohen Feit G, Feiglin A, Liu W, Hermida-Prado F, Kesten N, ... ... Zhao JJ, et al. Selective CDK7 inhibition suppresses cell cycle progression and MYC signaling while enhancing apoptosis in therapy-resistant estrogen receptor positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38381406 DOI: 10.1158/1078-0432.CCR-23-2975 |
0.394 |
|
| 2023 |
Bergholz JS, Wang Q, Wang Q, Ramseier M, Prakadan S, Wang W, Fang R, Kabraji S, Zhou Q, Gray GK, Abell-Hart K, Xie S, Guo X, Gu H, Von T, ... ... Zhao JJ, et al. PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature. PMID 37076617 DOI: 10.1038/s41586-023-05940-w |
0.353 |
|
| 2023 |
Ding L, Wang Q, Martincuks A, Kearns MJ, Jiang T, Lin Z, Cheng X, Qian C, Xie S, Kim HJ, Launonen IM, Färkkilä A, Roberts TM, Freeman GJ, Liu JF, ... ... Zhao JJ, et al. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer. Journal For Immunotherapy of Cancer. 11. PMID 36609487 DOI: 10.1136/jitc-2022-005627 |
0.3 |
|
| 2022 |
Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, ... ... Zhao JJ, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nature Communications. 13: 3022. PMID 35641483 DOI: 10.1038/s41467-022-30568-1 |
0.304 |
|
| 2022 |
Goel S, Bergholz JS, Zhao JJ. Targeting CDK4 and CDK6 in cancer. Nature Reviews. Cancer. PMID 35304604 DOI: 10.1038/s41568-022-00456-3 |
0.592 |
|
| 2022 |
Ni J, Kabraji S, Xie S, Wang Y, Pan P, He X, Liu Z, Leone JP, Long HW, Brown MA, Winer EP, Dillon DAR, Lin NU, Zhao JJ. p16-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nature Communications. 13: 1473. PMID 35304445 DOI: 10.1038/s41467-022-29081-2 |
0.347 |
|
| 2022 |
Gaglia G, Kabraji S, Rammos D, Dai Y, Verma A, Wang S, Mills CE, Chung M, Bergholz JS, Coy S, Lin JR, Jeselsohn R, Metzger O, Winer EP, Dillon DA, ... Zhao JJ, et al. Temporal and spatial topography of cell proliferation in cancer. Nature Cell Biology. 24: 316-326. PMID 35292783 DOI: 10.1038/s41556-022-00860-9 |
0.314 |
|
| 2021 |
Watt AC, Cejas P, DeCristo MJ, Metzger-Filho O, Lam EYN, Qiu X, BrinJones H, Kesten N, Coulson R, Font-Tello A, Lim K, Vadhi R, Daniels VW, Montero J, Taing L, ... ... Zhao JJ, et al. CDK4/6 inhibition reprograms the breast cancer enhancer landscape by stimulating AP-1 transcriptional activity. Nature Cancer. 2: 34-48. PMID 33997789 DOI: 10.1038/s43018-020-00135-y |
0.617 |
|
| 2020 |
Spangle JM, Von T, Pavlick DC, Khotimsky A, Zhao JJ, Roberts TM. PIK3CA C-terminal frameshift mutations are novel oncogenic events that sensitize tumors to PI3K-α inhibition. Proceedings of the National Academy of Sciences of the United States of America. PMID 32929011 DOI: 10.1073/Pnas.2000060117 |
0.334 |
|
| 2020 |
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, Feit AS, Bergholz J, Michowski W, Otto T, Sheng Q, Loo A, Michael W, Tiedt R, DeAngelis C, ... ... Zhao JJ, et al. Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition. Science Advances. 6: eabb2210. PMID 32704543 DOI: 10.1126/Sciadv.Abb2210 |
0.421 |
|
| 2020 |
Ding L, Wang Q, Kearns M, Jiang T, Konstantinopoulos P, Matulonis U, Zhao J. Abstract IA17: PARP inhibition modulates the tumor immune microenvironment in Brca1-deficient ovarian tumor Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-Ia17 |
0.397 |
|
| 2020 |
Leone JP, Trippa L, Milisits L, Andrews C, Ligibel J, Parsons H, Bi WL, Zhao J, Winer EP, Lin NU. Abstract OT1-08-05: Phase II trial of GDC-0084 in combination with trastuzumab for patients with HER2-positive breast cancer brain metastases (BCBM) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Ot1-08-05 |
0.414 |
|
| 2019 |
Sun B, Mason S, Wilson RC, Hazard SE, Wang Y, Fang R, Wang Q, Yeh ES, Yang M, Roberts TM, Zhao JJ, Wang Q. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers. Oncogene. PMID 31462705 DOI: 10.1038/S41388-019-0953-9 |
0.488 |
|
| 2019 |
Ni J, Wang Y, Diala I, Kabraji S, Freedman R, Lin N, Zhao J. Abstract 4832: Preclinical evaluation of neratinib plus T-DM1 in orthotopic PDX models of HER2-positive breast cancer brain metastases Cancer Research. 79: 4832-4832. DOI: 10.1158/1538-7445.Sabcs18-4832 |
0.461 |
|
| 2019 |
Bhola PD, Ahmed E, Guerriero J, Sicinska E, Su E, Ni J, Lavrova E, Chipashvili O, Hagan T, Ng K, Aguirre A, Lorch J, George S, Demetri G, Zhao J, et al. Abstract 4478: High-throughput dynamic BH3 profiling identifies active cancer therapies in solid tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-4478 |
0.342 |
|
| 2019 |
Ni J, Wang Y, Diala I, Kabraji S, Freedman R, Lin N, Zhao J. THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES Neuro-Oncology Advances. 1: i13-i13. DOI: 10.1093/NOAJNL/VDZ014.055 |
0.337 |
|
| 2018 |
Wang Y, Li BB, Li J, Roberts TM, Zhao JJ. A Conditional Dependency on MELK for the Proliferation of Triple-Negative Breast Cancer Cells. Iscience. 9: 149-160. PMID 30391850 DOI: 10.1016/J.Isci.2018.10.015 |
0.428 |
|
| 2018 |
Li AG, Murphy EC, Culhane AC, Powell E, Wang H, Bronson RT, Von T, Giobbie-Hurder A, Gelman RS, Briggs KJ, Piwnica-Worms H, Zhao JJ, Kung AL, Kaelin WG, Livingston DM. BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation. Proceedings of the National Academy of Sciences of the United States of America. PMID 30254159 DOI: 10.1073/Pnas.1807112115 |
0.385 |
|
| 2018 |
Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest. Trends in Cell Biology. PMID 30061045 DOI: 10.1016/J.Tcb.2018.07.002 |
0.633 |
|
| 2018 |
Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, Dai C, Hagel K, Hong AL, Gjoerup O, Goel S, ... ... Zhao JJ, et al. An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. Elife. 7. PMID 30059005 DOI: 10.7554/Elife.37184 |
0.526 |
|
| 2018 |
Sun B, Wang G, Liu H, Liu P, Twal WO, Cheung H, Carroll SL, Ethier SP, Mevers EE, Clardy J, Roberts T, Chen C, Li Q, Wang L, Yang M, ... Zhao JJ, et al. Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget. 9: 23878-23889. PMID 29844859 DOI: 10.18632/Oncotarget.24378 |
0.482 |
|
| 2018 |
Pal S, Kozono D, Yang X, Fendler W, Fitts W, Ni J, Alberta JA, Zhao J, Liu KX, Bian J, Truffaux N, Weiss WA, Resnick AC, Bandopadhayay P, Ligon KL, et al. Dual HDAC and PI3K inhibition abrogates NFκB- and FOXM1-mediated DNA damage response to radiosensitize pediatric high-grade gliomas. Cancer Research. PMID 29760046 DOI: 10.1158/0008-5472.Can-17-3691 |
0.367 |
|
| 2018 |
Wang Y, Li YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, ... ... Zhao JJ, et al. Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 7. PMID 29528283 DOI: 10.7554/Elife.36414 |
0.734 |
|
| 2018 |
Bergholz JS, Roberts TM, Zhao JJ. Isoform-Selective Phosphatidylinositol 3-Kinase Inhibition in Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017770891. PMID 29517943 DOI: 10.1200/Jco.2017.77.0891 |
0.385 |
|
| 2018 |
Zhou Z, Li M, Zhang L, Zhao H, Şahin Ö, Chen J, Zhao JJ, Songyang Z, Yu D. Oncogenic kinase-induced PKM2 tyrosine 105 phosphorylation converts non-oncogenic PKM2 to a tumor promoter and induces cancer stem-like cells. Cancer Research. PMID 29440169 DOI: 10.1158/0008-5472.Can-17-2726 |
0.435 |
|
| 2018 |
Jeselsohn R, Bergholz JS, Pun M, Cornwell M, Liu W, Nardone A, Xiao T, Li W, Qiu X, Buchwalter G, Feiglin A, Abell-Hart K, Fei T, Rao P, Long H, ... ... Zhao J, et al. Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 33: 173-186.e5. PMID 29438694 DOI: 10.1016/J.Ccell.2018.01.004 |
0.368 |
|
| 2018 |
Hemmati S, Sinclair T, Tong M, Bartholdy B, Okabe R, Ames K, Ostrodka L, Haque T, Kaur I, Agarwal A, Zhao J, Roberts T, Gritsman K. PI3Kinase Alpha and Delta Promote Hematopoietic Stem Activation Under Stress Blood. 132: 329-329. DOI: 10.1182/Blood-2018-99-114891 |
0.381 |
|
| 2018 |
Zhao J. Abstract IA22: Integrating immunotherapy and targeted therapy in breast cancer Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia22 |
0.511 |
|
| 2018 |
Pal S, Kozono D, Yang X, Fitts W, Ni J, Alberta J, Zhao J, Liu K, Bian J, Truffaux N, Weiss W, Resnick A, Bandhopadhayay P, Ligon K, DuBois S, et al. HGG-36. NFκB AND FOXM1 MEDIATE ANTI-CANCER ACTIVITY OF DUAL HDAC AND PI3K INHIBITION IN PEDIATRIC HIGH GRADE GLIOMA AND DIPG Neuro-Oncology. 20. DOI: 10.1093/Neuonc/Noy059.308 |
0.406 |
|
| 2017 |
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, Ni J, Duveau DY, Morris PJ, Zhao JJ, Thomas CJ, Monje M. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 549: 533-537. PMID 28959975 DOI: 10.1038/Nature24014 |
0.311 |
|
| 2017 |
Huang HT, Seo HS, Zhang T, Wang Y, Jiang B, Li Q, Buckley DL, Nabet B, Roberts JM, Paulk J, Dastjerdi S, Winter GE, McLauchlan H, Moran J, Bradner JE, ... ... Zhao JJ, et al. MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 6. PMID 28926338 DOI: 10.7554/Elife.26693 |
0.36 |
|
| 2017 |
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, Khan N, Ubellacker JM, Xie S, Metzger-Filho O, Hoog J, Ellis MJ, Ma CX, Ramm S, Krop IE, ... ... Zhao JJ, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. PMID 28813415 DOI: 10.1038/Nature23465 |
0.576 |
|
| 2017 |
Simond AM, Rao T, Zuo D, Zhao JJ, Muller WJ. ErbB2-positive mammary tumors can escape PI3K-p110α loss through downregulation of the Pten tumor suppressor. Oncogene. PMID 28783168 DOI: 10.1038/onc.2017.264 |
0.351 |
|
| 2017 |
Zhang J, Gao X, Schmit F, Adelmant G, Eck MJ, Marto JA, Zhao JJ, Roberts TM. CRKL Mediates p110β-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Reports. 20: 549-557. PMID 28723560 DOI: 10.1016/J.Celrep.2017.06.054 |
0.44 |
|
| 2017 |
Thorpe LM, Spangle JM, Ohlson CE, Cheng H, Roberts TM, Cantley LC, Zhao JJ. PI3K-p110α mediates the oncogenic activity induced by loss of the novel tumor suppressor PI3K-p85α. Proceedings of the National Academy of Sciences of the United States of America. PMID 28630349 DOI: 10.1073/Pnas.1704706114 |
0.423 |
|
| 2017 |
Hydbring P, Wang Y, Fassl A, Li X, Matia V, Otto T, Choi YJ, Sweeney KE, Suski JM, Yin H, Bogorad RL, Goel S, Yuzugullu H, Kauffman KJ, Yang J, ... ... Zhao JJ, et al. Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell. 31: 576-590.e8. PMID 28399412 DOI: 10.1016/J.Ccell.2017.03.004 |
0.493 |
|
| 2017 |
Spangle JM, Roberts TM, Zhao JJ. The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer. Biochimica Et Biophysica Acta. PMID 28315368 DOI: 10.1016/J.Bbcan.2017.03.002 |
0.374 |
|
| 2017 |
Filho OM, Goel S, Barry WT, Hamilton EP, Tolaney SM, Yardley DA, Rees R, Demeo M, Mills C, Hafner M, Winer EP, Zhao J, Krop IE. A mouse-human phase I co-clinical trial of taselisib in combination with TDM1 in advanced HER2-positive breast cancer (MBC). Journal of Clinical Oncology. 35: 1030-1030. DOI: 10.1200/Jco.2017.35.15_Suppl.1030 |
0.542 |
|
| 2016 |
Yuzugullu H, Von T, Thorpe LM, Walker SR, Roberts TM, Frank DA, Zhao JJ. NTRK2 activation cooperates with PTEN deficiency in T-ALL through activation of both the PI3K-AKT and JAK-STAT3 pathways. Cell Discovery. 2: 16030. PMID 27672444 DOI: 10.1038/Celldisc.2016.30 |
0.369 |
|
| 2016 |
Wang Y, Begley M, Li Q, Huang HT, Lako A, Eck MJ, Gray NS, Mitchison TJ, Cantley LC, Zhao JJ. Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proceedings of the National Academy of Sciences of the United States of America. PMID 27528663 DOI: 10.1073/Pnas.1606862113 |
0.355 |
|
| 2016 |
Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H, Liu P. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecologic Oncology. PMID 27426307 DOI: 10.1016/J.Ygyno.2016.07.092 |
0.379 |
|
| 2016 |
Goel S, Zhao JJ. CDK4/6 inhibition: the late harvest cycle begins. Oncotarget. PMID 27391058 DOI: 10.18632/Oncotarget.9576 |
0.558 |
|
| 2016 |
Spangle JM, Dreijerink KM, Groner AC, Cheng H, Ohlson CE, Reyes J, Lin CY, Bradner J, Zhao JJ, Roberts TM, Brown M. PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Reports. PMID 27292631 DOI: 10.1016/J.Celrep.2016.05.046 |
0.441 |
|
| 2016 |
Ni J, Ramkissoon SH, Xie S, Goel S, Stover DG, Guo H, Luu V, Marco E, Ramkissoon LA, Kang YJ, Hayashi M, Nguyen QD, Ligon AH, Du R, Claus EB, ... ... Zhao JJ, et al. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nature Medicine. PMID 27270588 DOI: 10.1038/Nm.4120 |
0.581 |
|
| 2016 |
Saito K, He Y, Yang Y, Zhu L, Wang C, Xu P, Hinton AO, Yan X, Zhao J, Fukuda M, Tong Q, Clegg DJ, Xu Y. PI3K in the ventromedial hypothalamic nucleus mediates estrogenic actions on energy expenditure in female mice. Scientific Reports. 6: 23459. PMID 26988598 DOI: 10.1038/Srep23459 |
0.331 |
|
| 2016 |
Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, ... ... Zhao JJ, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 29: 255-269. PMID 26977878 DOI: 10.1016/J.Ccell.2016.02.006 |
0.62 |
|
| 2016 |
Wang D, Wang M, Jiang N, Zhang Y, Bian X, Wang X, Roberts TM, Zhao JJ, Liu P, Cheng H. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. PMID 26909613 DOI: 10.18632/Oncotarget.7549 |
0.408 |
|
| 2015 |
Cheng H, Liu P, Ohlson C, Xu E, Symonds L, Isabella A, Muller WJ, Lin NU, Krop IE, Roberts TM, Winer EP, Arteaga CL, Zhao JJ. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. PMID 26640141 DOI: 10.1038/Onc.2015.377 |
0.426 |
|
| 2015 |
Wang Q, Liu P, Spangle JM, Von T, Roberts TM, Lin NU, Krop IE, Winer EP, Zhao JJ. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. PMID 26500061 DOI: 10.1038/Onc.2015.406 |
0.446 |
|
| 2015 |
Yuzugullu H, Baitsch L, Von T, Steiner A, Tong H, Ni J, Clayton LK, Bronson R, Roberts TM, Gritsman K, Zhao JJ. A PI3K p110β-Rac signalling loop mediates Pten-loss-induced perturbation of haematopoiesis and leukaemogenesis. Nature Communications. 6: 8501. PMID 26442967 DOI: 10.1038/Ncomms9501 |
0.689 |
|
| 2015 |
Wang Y, Zhang T, Kwiatkowski N, Abraham BJ, Lee TI, Xie S, Yuzugullu H, Von T, Li H, Lin Z, Stover DG, Lim E, Wang ZC, Iglehart JD, Young RA, ... ... Zhao JJ, et al. CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer. Cell. 163: 174-186. PMID 26406377 DOI: 10.1016/J.Cell.2015.08.063 |
0.43 |
|
| 2015 |
Zhu L, Xu P, Cao X, Yang Y, Hinton AO, Xia Y, Saito K, Yan X, Zou F, Ding H, Wang C, Yan C, Saha P, Khan SA, Zhao J, et al. The ERα-PI3K Cascade in Pro-opiomelanocortin Progenitor Neurons Regulates Feeding and Glucose Balance in Female Mice. Endocrinology. en20151660. PMID 26375425 DOI: 10.1210/En.2015-1660 |
0.303 |
|
| 2015 |
Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, Huang A, Wang Y, Nishtala M, Hall B, Rikova K, Zhao J, Hirsch E, Benes CH, Engelman JA. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell. 27: 97-108. PMID 25544637 DOI: 10.1016/J.Ccell.2014.11.007 |
0.548 |
|
| 2015 |
Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nature Reviews. Cancer. 15: 7-24. PMID 25533673 DOI: 10.1038/nrc3860 |
0.328 |
|
| 2014 |
Li N, Fassl A, Chick J, Inuzuka H, Li X, Mansour MR, Liu L, Wang H, King B, Shaik S, Gutierrez A, Ordureau A, Otto T, Kreslavsky T, Baitsch L, ... ... Zhao JJ, et al. Cyclin C is a haploinsufficient tumour suppressor. Nature Cell Biology. 16: 1080-91. PMID 25344755 DOI: 10.1038/Ncb3046 |
0.685 |
|
| 2014 |
Wang Y, Lee YM, Baitsch L, Huang A, Xiang Y, Tong H, Lako A, Von T, Choi C, Lim E, Min J, Li L, Stegmeier F, Schlegel R, Eck MJ, ... ... Zhao JJ, et al. MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 3: e01763. PMID 24844244 DOI: 10.7554/Elife.01763 |
0.735 |
|
| 2014 |
Schmit F, Utermark T, Zhang S, Wang Q, Von T, Roberts TM, Zhao JJ. PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proceedings of the National Academy of Sciences of the United States of America. 111: 6395-400. PMID 24737887 DOI: 10.1073/Pnas.1323004111 |
0.309 |
|
| 2014 |
Cheng H, Liu P, Zhang F, Xu E, Symonds L, Ohlson CE, Bronson RT, Maira SM, Di Tomaso E, Li J, Myers AP, Cantley LC, Mills GB, Zhao JJ. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition. Cancer Research. 74: 15-23. PMID 24322983 DOI: 10.1158/0008-5472.Can-13-0544 |
0.351 |
|
| 2013 |
Filbin MG, Dabral SK, Pazyra-Murphy MF, Ramkissoon S, Kung AL, Pak E, Chung J, Theisen MA, Sun Y, Franchetti Y, Sun Y, Shulman DS, Redjal N, Tabak B, Beroukhim R, ... ... Zhao J, et al. Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nature Medicine. 19: 1518-23. PMID 24076665 DOI: 10.1038/Nm.3328 |
0.412 |
|
| 2013 |
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/Pnas.1303204110 |
0.41 |
|
| 2013 |
Wang Q, Von T, Bronson R, Ruan M, Mu W, Huang A, Maira SM, Zhao JJ. Spatially distinct roles of class Ia PI3K isoforms in the development and maintenance of PTEN hamartoma tumor syndrome. Genes & Development. 27: 1568-80. PMID 23873941 DOI: 10.1101/gad.216069.113 |
0.308 |
|
| 2013 |
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research. 73: 4075-85. PMID 23633485 DOI: 10.1158/0008-5472.Can-12-4579 |
0.395 |
|
| 2013 |
Jia S, Gao X, Lee SH, Maira SM, Wu X, Stack EC, Signoretti S, Loda M, Zhao JJ, Roberts TM. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discovery. 3: 44-51. PMID 23258246 DOI: 10.1158/2159-8290.Cd-12-0262 |
0.307 |
|
| 2013 |
Liu P, Cheng H, Symonds L, Xu E, Maira S, Tomaso Ed, Roberts T, Zhao J. Abstract 2713: The Pten and p53 tumor suppressors cooperate to constrain the PI3K/mTOR pathway activation. Cancer Research. 73: 2713-2713. DOI: 10.1158/1538-7445.Am2013-2713 |
0.413 |
|
| 2012 |
Utermark T, Rao T, Cheng H, Wang Q, Lee SH, Wang ZC, Iglehart JD, Roberts TM, Muller WJ, Zhao JJ. The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis. Genes & Development. 26: 1573-86. PMID 22802530 DOI: 10.1101/Gad.191973.112 |
0.324 |
|
| 2012 |
Ni J, Liu Q, Xie S, Carlson C, Von T, Vogel K, Riddle S, Benes C, Eck M, Roberts T, Gray N, Zhao J. Functional characterization of an isoform-selective inhibitor of PI3K-p110β as a potential anticancer agent. Cancer Discovery. 2: 425-33. PMID 22588880 DOI: 10.1158/2159-8290.Cd-12-0003 |
0.369 |
|
| 2012 |
Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, Thoreen CC, Wang J, Ni J, Patricelli MP, Vogel K, Riddle S, Waller DL, Traynor R, Sanda T, Zhao Z, ... ... Zhao J, et al. Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. The Journal of Biological Chemistry. 287: 9742-52. PMID 22223645 DOI: 10.1074/Jbc.M111.304485 |
0.396 |
|
| 2012 |
Shrestha Y, Schafer EJ, Boehm JS, Thomas SR, He F, Du J, Wang S, Barretina J, Weir BA, Zhao JJ, Polyak K, Golub TR, Beroukhim R, Hahn WC. PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling. Oncogene. 31: 3397-408. PMID 22105362 DOI: 10.1038/Onc.2011.515 |
0.462 |
|
| 2012 |
Gritsman K, Clayton L, Gilliland DG, Roberts TM, Zhao J. The p110alpha and p110delta Isoforms of PI3 Kinase Are Dispensable for Hematopoietic Stem Cell Self-Renewal but Have Redundant Roles in B Cell Differentiation. Blood. 120: 2322-2322. DOI: 10.1182/Blood.V120.21.2322.2322 |
0.374 |
|
| 2011 |
Li Y, Zhang Q, Tian R, Wang Q, Zhao JJ, Iglehart JD, Wang ZC, Richardson AL. Lysosomal transmembrane protein LAPTM4B promotes autophagy and tolerance to metabolic stress in cancer cells. Cancer Research. 71: 7481-9. PMID 22037872 DOI: 10.1158/0008-5472.Can-11-0940 |
0.3 |
|
| 2011 |
Liu P, Cheng H, Santiago S, Raeder M, Zhang F, Isabella A, Yang J, Semaan DJ, Chen C, Fox EA, Gray NS, Monahan J, Schlegel R, Beroukhim R, Mills GB, ... Zhao JJ, et al. Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nature Medicine. 17: 1116-20. PMID 21822287 DOI: 10.1038/Nm.2402 |
0.348 |
|
| 2010 |
Chittenden TW, Pak J, Rubio R, Cheng H, Holton K, Prendergast N, Glinskii V, Cai Y, Culhane A, Bentink S, Schwede M, Mar JC, Howe EA, Aryee M, Sultana R, ... ... Zhao JJ, et al. Therapeutic implications of GIPC1 silencing in cancer. Plos One. 5: e15581. PMID 21209904 DOI: 10.1371/Journal.Pone.0015581 |
0.432 |
|
| 2010 |
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, ... ... Zhao JJ, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature. 468: 968-72. PMID 21107320 DOI: 10.1038/Nature09627 |
0.321 |
|
| 2009 |
Zhao JJ, Silver DP. Estrogen receptor-negative breast cancer: new insights into subclassification and targeting. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 6309-10. PMID 19825953 DOI: 10.1158/1078-0432.CCR-09-2010 |
0.305 |
|
| 2009 |
Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews. Drug Discovery. 8: 627-44. PMID 19644473 DOI: 10.1038/Nrd2926 |
0.356 |
|
| 2009 |
Cheng H, Liu P, Wang ZC, Zou L, Santiago S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, Hahn WC, Zhao JJ. SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis. Science Signaling. 2: ra35. PMID 19622832 DOI: 10.1126/Scisignal.2000369 |
0.377 |
|
| 2009 |
Maurer M, Su T, Saal LH, Koujak S, Hopkins BD, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim DI, Ferris JS, Gruvberger-Saal SK, Laakso M, ... ... Zhao JJ, et al. 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Research. 69: 6299-306. PMID 19602588 DOI: 10.1158/0008-5472.Can-09-0820 |
0.455 |
|
| 2009 |
Jia S, Roberts TM, Zhao JJ. Should individual PI3 kinase isoforms be targeted in cancer? Current Opinion in Cell Biology. 21: 199-208. PMID 19200708 DOI: 10.1016/J.Ceb.2008.12.007 |
0.39 |
|
| 2008 |
Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 454: 776-9. PMID 18594509 DOI: 10.1038/Nature07091 |
0.343 |
|
| 2007 |
Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/J.Cell.2007.03.052 |
0.449 |
|
| 2007 |
Gjoerup OV, Wu J, Chandler-Militello D, Williams GL, Zhao J, Schaffhausen B, Jat PS, Roberts TM. Surveillance mechanism linking Bub1 loss to the p53 pathway. Proceedings of the National Academy of Sciences of the United States of America. 104: 8334-9. PMID 17488820 DOI: 10.1073/Pnas.0703164104 |
0.389 |
|
| 2006 |
Zhao JJ, Roberts TM. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Science's Stke : Signal Transduction Knowledge Environment. 2006: pe52. PMID 17164467 DOI: 10.1126/Stke.3652006Pe52 |
0.376 |
|
| 2005 |
Westbrook TF, Martin ES, Schlabach MR, Leng Y, Liang AC, Feng B, Zhao JJ, Roberts TM, Mandel G, Hannon GJ, Depinho RA, Chin L, Elledge SJ. A genetic screen for candidate tumor suppressors identifies REST. Cell. 121: 837-48. PMID 15960972 DOI: 10.1016/J.Cell.2005.03.033 |
0.302 |
|
| 2004 |
Zhao JJ, Roberts TM, Hahn WC. Functional genetics and experimental models of human cancer. Trends in Molecular Medicine. 10: 344-50. PMID 15242683 DOI: 10.1016/J.Molmed.2004.05.005 |
0.339 |
|
| Show low-probability matches. |